CSF3 and breast cancer: In particular, the mTOR pathway drives G-CSF expression in in vivo preclinical models of BC, where, notably, the CSC compartment exhibits an elevated production of G-CSF, thus identifying a positive correlation between CSCs and immunosuppressive TME (11).